STERIS plc

NYSE:STE Stock Report

Market Cap: US$22.7b

STERIS Management

Management criteria checks 4/4

STERIS' CEO is Dan Carestio, appointed in Jul 2021, has a tenure of 4.5 years. total yearly compensation is $10.67M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 0.057% of the company’s shares, worth $12.95M. The average tenure of the management team and the board of directors is 5 years and 8.4 years respectively.

Key information

Dan Carestio

Chief executive officer

US$10.7m

Total compensation

CEO salary percentage9.97%
CEO tenure4yrs
CEO ownership0.06%
Management average tenure5yrs
Board average tenure8.4yrs

Recent management updates

Recent updates

Is There Now An Opportunity In STERIS plc (NYSE:STE)?

Jul 06
Is There Now An Opportunity In STERIS plc (NYSE:STE)?

Is Now The Time To Put STERIS (NYSE:STE) On Your Watchlist?

May 23
Is Now The Time To Put STERIS (NYSE:STE) On Your Watchlist?

Is There An Opportunity With STERIS plc's (NYSE:STE) 33% Undervaluation?

May 07
Is There An Opportunity With STERIS plc's (NYSE:STE) 33% Undervaluation?

Is STERIS (NYSE:STE) A Risky Investment?

Apr 19
Is STERIS (NYSE:STE) A Risky Investment?

Risks To Shareholder Returns Are Elevated At These Prices For STERIS plc (NYSE:STE)

Apr 01
Risks To Shareholder Returns Are Elevated At These Prices For STERIS plc (NYSE:STE)

Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'

Mar 22

Is Now An Opportune Moment To Examine STERIS plc (NYSE:STE)?

Feb 06
Is Now An Opportune Moment To Examine STERIS plc (NYSE:STE)?

STERIS plc (NYSE:STE) Shares Could Be 41% Below Their Intrinsic Value Estimate

Jan 19
STERIS plc (NYSE:STE) Shares Could Be 41% Below Their Intrinsic Value Estimate

STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet

Jan 01
STERIS (NYSE:STE) Has A Pretty Healthy Balance Sheet

STERIS plc's (NYSE:STE) Popularity With Investors Is Clear

Dec 14
STERIS plc's (NYSE:STE) Popularity With Investors Is Clear

Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'

Nov 18

What Does STERIS plc's (NYSE:STE) Share Price Indicate?

Oct 19
What Does STERIS plc's (NYSE:STE) Share Price Indicate?

Is STERIS (NYSE:STE) A Risky Investment?

Oct 01
Is STERIS (NYSE:STE) A Risky Investment?

Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued

Sep 16

Earnings Tell The Story For STERIS plc (NYSE:STE)

Sep 13
Earnings Tell The Story For STERIS plc (NYSE:STE)
author-image

Robust Revenue Growth And Expanding Margins In The Medical Equipment Sector

Strong start to the fiscal year and gross margin improvements suggest underappreciated growth momentum and potential for expanding net margins.

Steris: Q2 Numbers Solidify Buy Thesis

Aug 13

STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 59% Above Its Share Price

Aug 08
STERIS plc's (NYSE:STE) Intrinsic Value Is Potentially 59% Above Its Share Price

Steris: Moving On, Losing Its Teeth

Apr 14

Steris: Strong Healthcare Products Growth Coupled With Weak AST Business

Feb 17

Steris: Comprehensive Sterilization Portfolios Tailored To Procedure Volumes

Nov 08

Steris: Remains On Track For Strong Fiscal '24, Added Upsides From Operating Leverage

Sep 01

Steris: Continuing To Grow The Product Lineup

Jun 20

CEO Compensation Analysis

How has Dan Carestio's remuneration changed compared to STERIS's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025US$11mUS$1m

US$610m

Dec 31 2024n/an/a

US$617m

Sep 30 2024n/an/a

US$591m

Jun 30 2024n/an/a

US$561m

Mar 31 2024US$10mUS$1m

US$551m

Dec 31 2023n/an/a

US$1b

Sep 30 2023n/an/a

US$1b

Jun 30 2023n/an/a

US$576m

Mar 31 2023US$8mUS$970k

US$557m

Dec 31 2022n/an/a

-US$28m

Sep 30 2022n/an/a

-US$8m

Jun 30 2022n/an/a

US$377m

Mar 31 2022US$6mUS$767k

US$285m

Dec 31 2021n/an/a

US$279m

Sep 30 2021n/an/a

US$250m

Jun 30 2021n/an/a

US$286m

Mar 31 2021US$3mUS$542k

US$397m

Dec 31 2020n/an/a

US$433m

Sep 30 2020n/an/a

US$424m

Jun 30 2020n/an/a

US$413m

Mar 31 2020US$2mUS$522k

US$408m

Dec 31 2019n/an/a

US$393m

Sep 30 2019n/an/a

US$336m

Jun 30 2019n/an/a

US$319m

Mar 31 2019US$2mUS$482k

US$304m

Compensation vs Market: Dan's total compensation ($USD10.67M) is about average for companies of similar size in the US market ($USD13.74M).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.


CEO

Dan Carestio (52 yo)

4yrs
Tenure
US$10,673,062
Compensation

Mr. Daniel A. Carestio, also known as Dan, serves as the Chief Executive Officer & President at STERIS plc since July 29, 2021. He had been Senior Vice President and Chief Operating Officer at STERIS plc s...


Leadership Team

NamePositionTenureCompensationOwnership
Daniel Carestio
President4yrsUS$10.67m0.057%
$ 12.9m
Michael Tokich
Senior VP & CFO17.3yrsUS$3.31m0.048%
$ 10.9m
John Zangerle
Senior VP12yrsUS$2.94m0.034%
$ 7.8m
Mary Fraser
SVP & Chief Human Resources Officer5yrsUS$1.89m0.011%
$ 2.6m
Cary Majors
Senior VP & President of Healthcare5.9yrsUS$2.22m0.012%
$ 2.6m
Karen Burton
VP & Chief Accounting Officer8.5yrsno data0.0044%
$ 1.0m
Julie Winter
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Julia Madsen
Senior VP & GM of Life Sciences5yrsno data0.0096%
$ 2.2m
Andrew Xilas
Senior VP & GM of Dental4.1yrsUS$1.92m0.0065%
$ 1.5m
Kenneth Kohler
Senior VP & GM of AST1.4yrsno data0.0035%
$ 802.5k
Renato Tamaro
VP & Corporate Treasurer7.9yrsno data0.0069%
$ 1.6m
Walter Rosebrough
CEO Emeritus & Senior Advisor4yrsUS$1.16mno data
5.0yrs
Average Tenure
57yo
Average Age

Experienced Management: STE's management team is seasoned and experienced (5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Daniel Carestio
President4.5yrsUS$10.67m0.057%
$ 12.9m
Richard Breeden
Independent Director17.3yrsUS$353.90k0.032%
$ 7.2m
Mohsen Sohi
Independent Chairman of the Board20yrsUS$503.87k0.023%
$ 5.2m
Jacqueline Kosecoff
Independent Director21.8yrsUS$348.79k0.027%
$ 6.1m
Cynthia Feldmann
Independent Director20.3yrsUS$349.85k0.0095%
$ 2.2m
Richard Steeves
Independent Director9.7yrsUS$349.92k0%
$ 0
Paul Martin
Independent Director4.2yrsUS$342.35k0%
$ 0
Nirav Shah
Independent Director7.2yrsUS$336.35k0.00030%
$ 68.0k
Christopher Holland
Independent Director5yrsUS$342.30k0.00059%
$ 133.8k
Esther Alegria
Independent Director2.2yrsUS$334.80kno data
8.4yrs
Average Tenure
66yo
Average Age

Experienced Board: STE's board of directors are considered experienced (8.4 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/27 05:30
End of Day Share Price 2025/07/25 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

STERIS plc is covered by 26 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel OwczarskiAvondale Partners
Michael PolarkBaird
Erin Wilson WrightBofA Global Research